- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Cisplatin & Gemcitabine, Cisplatin & Pemetrexed, Docetaxel & Gemcitabine, Pemetrexed & Gemcitabine
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 8
- States / cities
- Durham, North Carolina • Henderson, North Carolina • Laurinburg, North Carolina + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 601–624
of 3,563
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Nivolumab
- Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Los Angeles, California • Billings, Montana + 2 more
- Conditions
- Non-Small Cell Lung Carcinoma
- Interventions
- Motexafin gadolinium and pemetrexed
- Drug
- Lead sponsor
- Pharmacyclics LLC.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 11
- States / cities
- Huntington Beach, California • Long Beach, California • Chicago, Illinois + 8 more
- Conditions
- Lung Cancer, Non-Small Cell, Neoplasms
- Interventions
- Tumor biopsy
- Procedure
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Non-Small-Cell Lung Cancer
- Interventions
- CAB-AXL-ADC, PD-1 inhibitor
- Biological
- Lead sponsor
- BioAtla, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 32
- States / cities
- Duarte, California • Irvine, California • Los Angeles, California + 26 more
- Conditions
- Lung Cancer
- Interventions
- cisplatin, docetaxel, gemcitabine hydrochloride
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2002
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Stage IA Non-small Cell Lung Cancer, Lung Carcinoid Tumor
- Interventions
- Active Surveillance
- Other
- Lead sponsor
- University of Vermont Medical Center
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Burlington, Vermont
- Conditions
- Non-small Cell Lung Cancer, Progression of Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Recurrent
- Interventions
- Docetaxel, Tergenpumatucel-L, Indoximod
- Drug · Biological
- Lead sponsor
- NewLink Genetics Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 2
- States / cities
- St Louis, Missouri • Cincinnati, Ohio
- Conditions
- Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
- Interventions
- LY3537982, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,264 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 87
- States / cities
- Huntsville, Alabama • Gilbert, Arizona • Phoenix, Arizona + 72 more
- Conditions
- Lung Cancer, Non-small-cell Lung Carcinoma
- Interventions
- Tarceva (erlotinib HCl)
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 92
- States / cities
- Huntsville, Alabama • Anchorage, Alaska • Glendale, Arizona + 83 more
- Conditions
- Pancreatic Cancer, Liver Cancer, Lung Cancer, Lung Cancer Non-Small Cell Cancer (NSCLC), Lung Cancer Small Cell Lung Cancer (SCLC), Hepatobiliary Cancers, Hepatobiliary Cancers Liver, Hepatobiliary Cancers Hepatocellular Carcinoma (Hepatoma), Hepatobiliary Cancers Gallbladder, Hepatobiliary Cancers Bile Duct
- Interventions
- MR Imaging
- Procedure
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- HER2-mutant Non-Small Cell Lung Cancer
- Interventions
- neratinib, temsirolimus
- Drug
- Lead sponsor
- Puma Biotechnology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 15
- States / cities
- Duarte, California • Santa Monica, California • Aurora, Colorado + 10 more
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Atezolizumab, Bevacizumab
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer, Uterine Cancer
- Interventions
- NEO-201 in combination with pembrolizumab
- Drug
- Lead sponsor
- Precision Biologics, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Fairfax, Virginia
- Conditions
- Non-Small-Cell Lung Carcinoma
- Interventions
- Belinostat, carboplatin, paclitaxel and bevacizumab
- Drug
- Lead sponsor
- Holy Cross Hospital, Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Fort Lauderdale, Florida
- Conditions
- HER2-positive Breast Cancer, HER2-positive Biliary Tract Cancer, HER2-Positive Salivary Gland Carcinomas, HER2-Positive Advanced Solid Tumor
- Interventions
- GQ1001
- Drug
- Lead sponsor
- GeneQuantum Healthcare (Suzhou) Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- RAD001
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 23 Years to 76 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 4
- States / cities
- Washington D.C., District of Columbia • New Orleans, Louisiana • Dallas, Texas + 1 more
- Conditions
- Colorectal Cancer, Squamous Cell Head and Neck Cancer, Non-small Cell Lung Cancer, Triple Negative Breast Cancer, Other Tumors With EGFR Dependence
- Interventions
- MM-121, Irinotecan, Cetuximab
- Drug
- Lead sponsor
- Merrimack Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 4
- States / cities
- San Francisco, California • Boston, Massachusetts • Chapel Hill, North Carolina + 1 more
- Conditions
- Lung Neoplasm, Carcinoma Non-small Cell Lung Cancer Stage IIIA, Carcinoma Non-small Cell Lung Cancer Stage IIIB, Carcinoma Non-small Cell Lung Cancer Stage IV
- Interventions
- Lucanix™, Placebo Comparator
- Biological · Other
- Lead sponsor
- NovaRx Corporation
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 532 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 53
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 46 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Nintedanib (BIBF1120), Pemetrexed, B12, dexamethasone (or corticosteroid equivalent), placebo, Folic Acid
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 718 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 40
- States / cities
- Downy, California • Fountain Valley, California • Fullerton, California + 37 more
- Conditions
- Carcinoma, Non Small Cell Lung
- Interventions
- gemcitabine, carboplatin, cisplatin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2006
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Daily Stereotactic Body Radiotherapy, Non-Daily Stereotactic Body Radiotherapy
- Radiation
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 2
- States / cities
- Gainesville, Florida • Jacksonville, Florida
- Conditions
- Lung Cancer
- Interventions
- Alimta
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2015
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Lung Cancer, NSCLC
- Interventions
- Atezolizumab, Docetaxel, Cisplatin, Pemetrexed
- Drug
- Lead sponsor
- Nasser Hanna
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 9
- States / cities
- Chicago, Illinois • Indianapolis, Indiana • Berkeley Heights, New Jersey + 6 more